389 related articles for article (PubMed ID: 34106777)
1. Gender-specific cut-off levels in colorectal cancer screening with fecal immunochemical test: A population-based study of colonoscopy findings and costs.
Ribbing Wilén H; Saraste D; Blom J
J Med Screen; 2021 Dec; 28(4):439-447. PubMed ID: 34106777
[TBL] [Abstract][Full Text] [Related]
2. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
Ribbing Wilén H; Saraste D; Blom J
J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
[TBL] [Abstract][Full Text] [Related]
3. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
[TBL] [Abstract][Full Text] [Related]
4. Lower Abnormal Fecal Immunochemical Test Cut-Off Values Improve Detection of Colorectal Cancer in System-Level Screens.
Berry E; Miller S; Koch M; Balasubramanian B; Argenbright K; Gupta S
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):647-653. PubMed ID: 31085338
[TBL] [Abstract][Full Text] [Related]
5. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
6. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
[TBL] [Abstract][Full Text] [Related]
7. Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives.
Ribbing Wilén H; Blom J; Höijer J; Andersson G; Löwbeer C; Hultcrantz R
Scand J Gastroenterol; 2019 Mar; 54(3):303-310. PubMed ID: 30907196
[No Abstract] [Full Text] [Related]
8. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
[TBL] [Abstract][Full Text] [Related]
9. Piloting gender-oriented colorectal cancer screening with a faecal immunochemical test: population-based registry study from Finland.
Sarkeala T; Färkkilä M; Anttila A; Hyöty M; Kairaluoma M; Rautio T; Voutilainen M; Helander S; Jäntti M; Lehtinen M; Patrikka L; Malila N; Heinävaara S
BMJ Open; 2021 Feb; 11(2):e046667. PubMed ID: 33558363
[TBL] [Abstract][Full Text] [Related]
10. Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening.
Alvarez-Urturi C; Andreu M; Hernandez C; Perez-Riquelme F; Carballo F; Ono A; Cruzado J; Cubiella J; Hernandez V; Mao CG; Perez E; Salas D; Andrés M; Bujanda L; Portillo I; Sarasqueta C; Quintero E; Morillas JD; Lanas A; Sostres C; Augé JM; Castells A; Bessa X;
Dig Liver Dis; 2016 May; 48(5):542-551. PubMed ID: 26936343
[TBL] [Abstract][Full Text] [Related]
11. Interval cancer after two rounds of a Swedish population-based screening program using gender-specific cut-off levels in fecal immunochemical test.
Ribbing Wilén H; Blom J
J Med Screen; 2024 Mar; 31(1):8-14. PubMed ID: 37455444
[TBL] [Abstract][Full Text] [Related]
12. Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening.
Kooyker A; de Jonge L; Toes-Zoutendijk E; Spaander M; van Vuuren H; Kuipers E; van Kemenade F; Ramakers C; Dekker E; Nagtegaal I; van Leerdam M; Lansdorp-Vogelaar I
Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3424-3432.e2. PubMed ID: 37619823
[TBL] [Abstract][Full Text] [Related]
13. Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).
Breekveldt ECH; Toes-Zoutendijk E; de Jonge L; Spaander MCW; Dekker E; van Kemenade FJ; van Vuuren AJ; Ramakers CRB; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
BMC Gastroenterol; 2023 Feb; 23(1):45. PubMed ID: 36814185
[TBL] [Abstract][Full Text] [Related]
14. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
[TBL] [Abstract][Full Text] [Related]
16. Fecal MicroRNA-Based Algorithm Increases Effectiveness of Fecal Immunochemical Test-Based Screening for Colorectal Cancer.
Duran-Sanchon S; Moreno L; Gómez-Matas J; Augé JM; Serra-Burriel M; Cuatrecasas M; Moreira L; Serradesanferm A; Pozo À; Grau J; Pellisé M; Gironella M; Castells A
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):323-330.e1. PubMed ID: 32113893
[TBL] [Abstract][Full Text] [Related]
17. Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia.
Kapidzic A; van der Meulen MP; Hol L; van Roon AH; Looman CW; Lansdorp-Vogelaar I; van Ballegooijen M; van Vuuren AJ; Reijerink JC; van Leerdam ME; Kuipers EJ
Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1464-71.e4. PubMed ID: 25724706
[TBL] [Abstract][Full Text] [Related]
18. [Diagnostic performance of quantitative fecal immunochemical test in detection of advanced colorectal neoplasia].
Lu M; Chen HD; Liu CC; Zhang YH; Wei LP; Lyu ZY; Ren JS; Shi JF; Zou SM; Li N; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Dec; 41(12):2104-2111. PubMed ID: 33378824
[No Abstract] [Full Text] [Related]
19. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of fecal immunochemical test and risk factors for interval colorectal cancer in a French population.
Canévet M; Pruvost-Couvreur M; Morvan M; Badic B; Brousse-Potocki J; Kermarrec T; Bouzeloc S; Nousbaum JB; Robaszkiewicz M; Reboux N; Quénéhervé L
Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102093. PubMed ID: 36764389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
